Organon & Co. Reports Q3 2025 Financial Results with $1.602 Billion Revenue

Organon & Co. reported its financial results for the third quarter of 2025, revealing revenues of $1.602 billion, a slight increase of 1% compared to $1.582 billion in the same period last year. For the nine months ending September 30, 2025, total revenues reached $4.709 billion, down 2% from $4.811 billion in the prior year. The company's net income for the quarter was $160 million, translating to earnings per share of $0.61, a significant decrease from $359 million and $1.39 per share in the third quarter of 2024. The decline in profitability was attributed to increased costs of sales and lower gross profit margins, which fell to $857 million from $923 million year-over-year.

The company experienced notable changes in its operational landscape, including the acquisition of Dermavant Sciences Ltd. in late 2024, which contributed to the launch of Vtama, a new product for treating atopic dermatitis. This acquisition, along with the launch of Hadlima, a biosimilar to Humira, positively impacted sales. However, sales of key products like Nexplanon and Atozet faced challenges due to lower demand and loss of exclusivity in certain markets, leading to a decrease in overall sales for these products. The company also reported a restructuring initiative that resulted in a 6% reduction in headcount, aimed at optimizing its operational model.

Geographically, Organon saw varied performance, with U.S. sales increasing by 2% to $406 million, while international sales grew by only 1% to $1.196 billion. The company noted that foreign exchange rates positively impacted revenues by approximately 2%. Despite these gains, the overall sales performance was hindered by competitive pressures and pricing challenges in several international markets, particularly in Asia and Europe. The company’s total assets increased to $13.552 billion as of September 30, 2025, up from $13.101 billion at the end of 2024, reflecting a strategic focus on expanding its product portfolio and market presence.

Looking ahead, Organon has acknowledged the need to address material weaknesses in its internal control over financial reporting, as identified during an internal investigation into sales practices related to Nexplanon. The company has implemented a remediation plan, including changes in leadership and enhanced compliance training. Despite these challenges, Organon remains committed to its strategic objectives, including the continued development of its women's health and general medicines portfolios. The company anticipates that ongoing efforts to optimize its operations and adapt to market conditions will support future growth and profitability.